Literature DB >> 30063259

Treatment Barriers in Portopulmonary Hypertension.

Batool AbuHalimeh1, Michael J Krowka2, Adriano R Tonelli3.   

Abstract

Portopulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH) that can develop as a complication of portal hypertension. Treatment of PoPH includes PAH-specific therapies, and in certain cases, such therapies are necessary to facilitate a successful liver transplantation. A significant number of barriers may limit the adequate treatment of patients with PoPH and explain the poorer survival of these patients when compared to patients with other types of PAH. Until recently, only one randomized controlled trial has included PoPH patients, and the majority of treatment data have been derived from relatively small observational studies. In the present article, we review some of the barriers in the treatment of patients with PoPH and implications for liver transplantation.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2018        PMID: 30063259      PMCID: PMC6460471          DOI: 10.1002/hep.30197

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  92 in total

Review 1.  The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough.

Authors:  Reiner Wiest; Roberto J Groszmann
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

2.  Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study.

Authors:  Isabelle O Colle; Richard Moreau; Erica Godinho; Jacques Belghiti; Florence Ettori; Alain Cohen-Solal; Hervé Mal; Jacques Bernuau; Jean Marty; Didier Lebrec; Dominique Valla; François Durand
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

3.  Bosentan therapy for pulmonary arterial hypertension.

Authors:  Lewis J Rubin; David B Badesch; Robyn J Barst; Nazzareno Galie; Carol M Black; Anne Keogh; Tomas Pulido; Adaani Frost; Sebastien Roux; Isabelle Leconte; Michael Landzberg; Gerald Simonneau
Journal:  N Engl J Med       Date:  2002-03-21       Impact factor: 91.245

4.  The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.

Authors:  K Fattinger; C Funk; M Pantze; C Weber; J Reichen; B Stieger; P J Meier
Journal:  Clin Pharmacol Ther       Date:  2001-04       Impact factor: 6.875

5.  Hepatic and splanchnic nitric oxide activity in patients with cirrhosis.

Authors:  A I Sarela; F M Mihaimeed; J J Batten; B R Davidson; R T Mathie
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

Review 6.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 7.  Quality of life in cirrhotics with minimal hepatic encephalopathy.

Authors:  H Schomerus; W Hamster
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

8.  Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.

Authors:  M J Krowka; R P Frantz; M D McGoon; C Severson; D J Plevak; R H Wiesner
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

9.  Sildenafil (viagra) is a risk factor for acute variceal bleeding.

Authors:  Charalabos Tzathas; Ageliki Christidou; Spiros D Ladas
Journal:  Am J Gastroenterol       Date:  2002-07       Impact factor: 10.864

Review 10.  Paracetamol toxicity and its prevention by cytoprotection with iloprost.

Authors:  D S Davies; D J Fawthrop; P Nasseri-Sina; J W Wilson; S J Hardwick; A R Boobis
Journal:  Toxicol Lett       Date:  1992-12       Impact factor: 4.372

View more
  7 in total

1.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.

Authors:  Kelley Weinfurtner; Kimberly Forde
Journal:  Curr Hepatol Rep       Date:  2020-07-11

2.  Predictors of survival in portopulmonary hypertension: a 20-year experience.

Authors:  Manik Aggarwal; Manshi Li; Abhishek Bhardwaj; William D Wallace; Xiaofeng Wang; William D Carey; Raed A Dweik; Gustavo A Heresi; Adriano R Tonelli
Journal:  Eur J Gastroenterol Hepatol       Date:  2022-04-01       Impact factor: 2.566

Review 3.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

Review 4.  Pulmonary manifestations of chronic liver disease: a comprehensive review.

Authors:  Stergios Soulaidopoulos; Ioannis Goulis; Evangelos Cholongitas
Journal:  Ann Gastroenterol       Date:  2020-03-27

5.  Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study.

Authors:  Sandeep Sahay; Yuen Tsang; Megan Flynn; Peter Agron; Robert Dufour
Journal:  Pulm Circ       Date:  2020-11-23       Impact factor: 3.017

6.  The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan.

Authors:  Yukiko Takahashi; Keiko Yamamoto; Seiichiro Sakao; Takao Takeuchi; Rika Suda; Nobuhiro Tanabe; Koichiro Tatsumi
Journal:  BMC Pulm Med       Date:  2021-03-16       Impact factor: 3.317

7.  Causes and Circumstances of Death in Portopulmonary Hypertension.

Authors:  Sandeep Sahay; Sami Al Abdi; Celia Melillo; Jennie Newman; Raed A Dweik; Gustavo A Heresi; Adriano R Tonelli
Journal:  Transplant Direct       Date:  2021-06-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.